Abstract: The aim of our study was to determine the effectiveness and toxicity of combined chemotherapy consisting of cladribine (2-chlorodeoxyadenosine, 2-CdA), mitoxantrone and cyclophosphamide (CMC regimen) in the treatment of refractory or relapsed indolent lymphoproliferative disorders. The treatment course consisted of 2-CdA given at a dose of 0.12 mg/kg/24 h in a 2-h intravenous infusion for 5 (CMC5) or 3 (CMC3) consecutive days, mitoxantrone 10 mg/m 2 on day 1 and cyclophosphamide 650 mg/m 2 /iv on day 1. Thirty-three patients (19 with B-CLL and 14 with LG-NHL) entered the study and all of them were eligible. Twenty patients (60.6%) were recurrent after prior therapy and 13 (39.4%) had refractory disease. All patients received 5 or more cycles of chemotherapy before CMC treatment. Twenty-one patients were treated with CMC5 regimen and 12 with CMC3 regimen. The overall response rate, including CR and PR, was 48.6% (95% CI 32±66). There were no differences in the frequency of responses between the CMC3 and CMC5 treated groups (p>0.05). One patient with B-CLL and three patients with lymphocytic lymphoma achieved CR (12.1%). Among 12 patients (36.4%) who achieved PR there were 6 CLL patients, and 6 lymphoma patients. The major toxicity was myelosuppression. Severe neutropenia was seen in 11/ 33 (33.3%) patients, more frequently in patients who received CMC5 than in the patients who received CMC3, both in the CLL (50.0% and 28.5%, respectively) and in the LG-NHL group (22.2% and 0%, respectively). The rate of thrombocytopenia was similar in both groups. Infections and fever of unknown origin complicated the treatment with CMC5 more often than with CMC3: ®ve episodes were seen in 3 patients treated with CMC3 when compared to 15 episodes in 12 patients treated with CMC5. In conclusion, the CMC programme is an active combined regimen in heavily pre-treated CLL and LG-NHL patients. However, its toxicity is signi®cant and we suggest a shortening of 2-CdA infusion from 5 to 3 d in further studies. Whether a combination of 2-CdA with cyclophosphamide and mitoxantrone would result in improved outcome as compared to 2-CdA alone, is being investigated in a prospective, randomised trial.
The long-term prognosis for patients with advanced relapsed or refractory indolent lymphoid malignancies remains poor. The most promising new agents in the treatment of chronic lymphocytic leukaemia (CLL) (1±3) and indolent lymphoma (4, 5) are purine analogues, especially¯udarabine (FAMP) and cladribine (2-CdA), because of their unique mechanisms of action by induction of apoptosis of lymphocytes. They may thus interfere with the pathogenesis of indolent lymphoid malignancies. Both agents give high overall response rates in previously treated and especially untreated patients (6±8). In a randomised study comparing the effectiveness of 2-CdA and FAMP in low-grade non-Hodgkin's lymphoma, the response rates and duration of remission were similar (9) . The results of randomised studies con®rm a higher response rate for FAMP and 2-CdA in comparison with chlorambucil or French CAP (9±12). However, no survival advantage for the patients treated with purine analogues has been observed so far (2, 12) , and the possibility of cure is doubtful.
In an attempt to further improve the treatment results and prolong survival, new purine analogues are combined with other drugs in LG-NHL and CLL treatment. However, there is still little experience in this area. Alkylating agents like cyclophosphamide have different mechanisms of antitumour activity. Pre-clinical studies indicate that FAMP and 2-CdA act synergistically with other cytotoxic agents including cyclophosphamide, cytosine arabinoside and other drugs (13±17). Clinical studies combining FAMP or 2-CdA with cyclophosphamide have also demonstrated signi®-cant activity in pre-treated patients with low-grade lymphoproliferative malignancies (18, 19) . A doseescalation study of cyclophosphamide added to 2-CdA in patients with previously treated CLL and LG-NHL showed the feasibility of this association, with an overall response rate of 58% and 15% CRs (20) . However, acute neutropenia was the main dose-relating toxicity. Laurencet et al. used 2-CdA with cyclophosphamide and prednisone in the management of patients with previously untreated low-grade lymphoproliferative malignancies (21) . They observed an overall response rate of 88%, with four patients achieving CR and 12 PR.
Furthermore, early clinical reports suggest that the combination of FAMP or 2-CdA with mitoxantrone and dexamethasone is an effective regimen for indolent lymphoma. Very impressive results were observed by McLaughlin et al. using a combination of FAMP, mitoxantrone and dexamethasone in patients with recurrent or relapsed indolent lymphoma (22) . McLaughlin et al. observed a 94% overall response rate with 47% CR. Also, the combination of 2-CdA with mitoxantrone used by Saven et al. and in our previous study resulted in a high response rate (23, 24) .
As the available results of pre-clinical and clinical studies of combination regimens of purine analogues and cyclophosphamide or anthracycline are encouraging, we designed a pilot phase I/II study to investigate the feasibility, ef®cacy and toxicity of the combined chemotherapy regimen consisting of 2-h intravenous infusion of 2-CdA given for 3 or 5 d with both mitoxantrone and cyclophosphamide in the treatment of patients with advanced B-cell chronic lymphoid malignancies (B-CLL and LG-NHL).
Patients and methods

Patients
Between August 1998 and August 2000 19 patients with B-CLL and 14 patients with LG-NHL entered the study after giving their informed consent.
The diagnosis was based on the criteria established by the NCI-Sponsored Working Group (25) for B-CLL and an updated Kiel classi®cation (26) for LG-NHL.
Immunophenotyping was performed on leukemic peripheral blood or bone marrow by¯ow cytometry using a simultaneous dual colour staining technique before treatment. Flow cytometry analysis was made by EPICS-XL (Coulter, Hialeah, FL, USA). A combination of phycoerythrin (PE)-conjugated and¯uorescein isothiocyanate (FITC)-conjugated monoclonal antibodies was used. Immunotype was determined using the monoclonal antibodies against the following antigens: CD19/CD5, CD19/CD23, CD20/CD5, CD19/CD22, CD3/CD4 and light chains kappa and lambda. A central pathology review was performed for every case. The clinical stage of CLL was determined at the time of initiation of CMC treatment according to the Rai classi®cation (27) .
All patients had to undergo treatment with conventional therapy including at least an alkylating agent and prednisone and either failed to respond (refractory disease) or developed progressive disease after initial response less than 6 months after the discontinuation of previous treatment (recurrent disease).
Pre-treatment evaluation included physical examination, complete blood count (CBC), reticulocyte count, Coombs test, a serum chemistry pro®le, including lactate dehydrogenase level (LDH), renal and liver function tests, serum immunoglobulin level quantitation, urinalysis, bone marrow biopsy, chest X-ray, ECG and imaging of abdomen with either computed tomography or ultrasonography. All patients had to be free of active infection and have a life expectancy greater than 3 months. The pretreatment characteristics of the patients are shown in Table 1 .
Treatment protocol
The treatment consisted of 2-CdA given at a dose of 0.12 mg/kg/d in a 2-h intravenous infusion for 5 (CMC5) or 3 (CMC3) consecutive days, mitoxantrone 10 mg/m 2 on day 1 and cyclophosphamide 650 mg/m 2 /iv on day 1. 2-CdA (Biodrybin) was synthesised according to the method of Kazimierczuk et al. (28) and was commercially available from the Institute of Biotechnology and Antibiotics, Bioton (Warsaw). The cycles were repeated, usually at 4 wk intervals. If a response was documented, patients were treated until maximal response or prohibitive toxicity. If no response or progression of the disease was observed after two cycles, the treatment was interrupted. In patients in whom the number of platelets was lower than 50r10 9 /l and/or the number of neutrophils was lower than 1r10 9 /l the drug was re-administered at time intervals longer than 4 wk, ranging from 5 to 8 wk. Packed red blood cells were transfused for symptomatic anaemia or prophylactically if the haemoglobin level was lower than 7.0 g/dl. Platelets were administered prophylactically if the platelet count was less than 15.0r10 9 /l. In order to prevent hyperuricemia, allopurinol (300 mg daily) was given. No patients received antibiotics prophylactically. Patients could receive hematopoietic growth factors (G-CSF or GM-CSF) if the absolute granulocyte count was less than 1.0r10 9 /l and an active infection was present. Therapy was discontinued if serum creatinine >2.0 mg/dl or bilirubin level and alkaline phosphatase or aminotranferases activity >2 times normal. The treatment was also delayed if active infection was present.
Response criteria
Complete response for CLL patients was de®ned according to the NCI-Sponsored Working Group as the absence of symptoms and organomegaly, a normal complete blood cell count (absolute neutrophil count >1.5r10 9 /l, hemoglobin concentration >11.0 g/dl, platelet count >100.0r10 9 /l) and bone marrow with less than 30% of lymphocytes for at least 2 months (25) . Partial response (PR) was considered as a 50% or greater decrease in the size of lymph nodes, liver or spleen, and peripheral blood ®ndings either identical to those of CR or improved over pre-therapy values by at least 50%.
CR for NH-LGL was de®ned as the disappearance of all evidence of disease by physical examination, bone marrow biopsy and radiological evaluation lasting at least 2 months with no development of any new lesions. In addition, a number of granulocytes greater than 1.5r10 9 /l and haemoglobin greater than 11.0 g/dl were required for at least 2 months. Partial response (PR) was de®ned as a reduction of at least 50% in all the involved areas of disease, lasting for at least 2 months. The duration of response was computed from the time of onset of PR or CR to the time of relapse, last follow-up, or death. Patients who had not achieved CR or PR were classi®ed as nonresponders. Response was assessed after each cycle. In the case of CR no further therapy was administered; in the case of PR, CMC was continued up to the maximum of six courses; non-responders were put on another treatment.
Toxicity criteria
Toxic effects were monitored and assessed according to World Health Organisation (WHO) criteria (29) . Blood counts, creatinine, bilirubin, GOT, GPT, ECG, urinalysis and general physical examinations were serially evaluated and recorded. Statistical analysis
The differences in response rates between groups were analysed with a chi-square test. Ninety-®ve percent con®dence intervals for response probability were calculated using the method described by Duffy and Santner (30) .
Results
Response
Thirty-three patients (19 with B-CLL and 14 with
LG-NHL) entered the study and all of them were eligible. Twenty patients (60.6%) were recurrent after prior therapy and 13 (39.4%) were refractory. All patients received 5 or more cycles of chemotherapy before CMC treatment. The characteristics of the patients are presented in Table 1 . Twenty-one patients were treated with the CMC5 regimen and 12 with the CMC3 regimen. The total number of CMC courses given to the entire group amounted 79 (50 CMC5 and 29 CMC3 courses). All patients received at least one CMC course. The median number of CMC5 cycles was 2.5 (range 1±4) and the median number of CMC3 cycles was 3 (range 2±4).
The overall response rate, including CR and PR, was 48.6% (95% CI 32±66). There were no differences in the frequency of responses between CMC3 and CMC5 treated groups (p>0.05). The response to CMC treatment according to the diagnosis and treatment protocol is summarised in Table 2 . One patient with B-CLL and three patients with LG-NHL (lymphocytic lymphoma) achieved CR (12.1%). All CRs were achieved after 3 courses of CMC, and their durations are 6, 4, 5+ and 4+ months, respectively. Interestingly, 6 months before treatment with CMC, one of the lymphoma patients had received four courses of CID regimen (2-CdA, idarubicin and dexamethasone) and achieved a PR that lasted only 10 wk. Among the 12 patients (36.4%) who achieved PR there were 6 CLL patients and 6 LG-NHL patients. Four patients were treated previously with 2-CdA Abbreviations: CR, complete remission; PR, partial remission; NR, no remission.
The differences in response rates between CMC3 and CMC5 treated groups were non-signi®cant (p<0.05). alone and one with anti-CD20 antibody (rituximab), without any effect. The detailed characteristics of responders are shown in Table 3 .
Toxicity
The major toxicity was myelosuppression. The detailed results are shown in Table 4 . Severe neutropenia was seen in 11/33 (33.3%) patients, more frequently in patients who received CMC5 than in patients who received CMC3, both in the CLL (50.0% and 28.5%, respectively) and in the LG-NHL groups (22.2% and 0%, respectively). The results are not signi®cant owing to the small number of patients. A similar pattern of haematological toxicity was seen in case of anaemia (5/21, 23.8% versus 1/12, 8.3% of patients). There was one case of pure red cell aplasia (PRCA) in a CLL patient after treatment with CMC5. Three patients in the CMC5 group required red cell transfusions for 1±3 months. The rate of thrombocytopenia was similar in both groups. Four patients in the CMC5 group and one patient in the CMC3 group received platelet transfusions for 2±8 wk. Haematological toxicity was the reason for discontinuing therapy after one course in three CMC5 treated patients and no CMC3 treated patients. Half of the patients in the CMC5 group and 30% of the CMC3 group had at least one infusion of the drugs delayed because of cytopenia. Non-haematological side-effects were mostly due to immunosuppression. Infections and fever of unknown origin complicated the treatment with CMC5 more often than with CMC3: ®ve episodes were seen in three patients treated with CMC3 when compared to 15 episodes in 13 patients treated with CMC5. In one patient treated with CMC3 and in two treated with CMC5 transient elevation of serum aminotransferases was observed. In three patients grade III vomiting according to the WHO classi®cation was observed.
Altogether, six patients died during the study. One patient died of sepsis and one because of pneumonia in the CMC5 group. Four patients died of disease progression (1 in the CMC3 and 3 in the CMC5 treated group).
Discussion
To our knowledge, the present trial in patients with indolent lymphomas is the ®rst study of the combination of 2-CdA with two other antineoplastic drugs, cyclophosphamide and mitoxantrone (the CMC program). The results of our study show that the CMC programme has signi®cant antineoplastic activity either in patients with CLL and LG-NHL resistant to prior chemotherapy or with early recurrence. In the present study 2-CdA was applied in the same daily dose (0.12 mg/kg/d) for 5 d (CMC5) or only for 3 d (CMC3). The overall response rate in these two CMC modalities was not signi®cantly different and was 47.6% in CMC3 and 50.0% in CMC5 (p>0.05). The overall response rate for all patients was 48.5%, including 12.1% CR. In the group of 16 patients who responded to CMC treatment there were ®ve patients who had been treated earlier with 2-CdA in monotherapy or in combination with idarubicin and one patient treated with rituximab. These patients had had no response to such treatment or only short PR. The ef®cacy of this programme seems to be similar to that observed by us earlier in patients with CLL or LG-NHL treated in our centre with 2-CdA in monotherapy or combined with prednisone (5, 31) . The rate of overall responses in the group of 19 CLL patients was 48.4% with 12.5% CRs and in 14 LG-NHL patients 51.1% and 12.8%, respectively. In our previous study we have also observed a similar response rate in heavily pre-treated patients with LG-NHL, in whom 2-CdA had been administered Abbreviations: n, number of patients; n 1 , number of courses; FUO, fever of unknown origin. The differences in toxicity between CMC3 and CMC5 treated groups were non-signi®cant (p<0.05).
in combination with dexamethasone and mitoxantrone or idarubicin (24, 32) . The ef®cacy of the CMC program is also similar to that observed earlier in CLL or LG-NHL by other authors who used 2-CdA as a single drug or in combination with alkylating agents or anthracyclines. Morton et al. applied 2-CdA in a dose of 0.14 mg/kg/d for 5 d in 27 relapsed LG-NHL patients with 49% OR (33) . Similar results were reported by Liliemark et al., who administered 2-CdA in a dose of 0.12 mg/kg/d in a 2 h iv infusion for 5 d in 36 LG-NHL patients, including 23 refractory to previous chemotherapy and in 13 relapsed patients (34) . The overall response rate was 42%, including 14% CR. Similarly, other authors did not observe better outcome for patients treated with combined chemotherapy, including 2-CdA and alkylating drugs or anthracyclines (18±23, 35±37).
Moreover, it was proved, similar to the results of our present study, that the administration of the same dose of 2-CdA in combined treatment as in monotherapy may lead to a toxicity level that is dif®cult to accept. Tefferi et al. in their phase I study in patients with refractory or relapsed CLL or LG-NHL evaluated the toxicity of 2-CdA administered at a dose of 1, 2 or 4 mg/kg/d in continuous iv infusion for 7 d combined with the standard dose chlorambucil (30 mg/m 2 per os, every 2 wk) (35). The conclusion was that 2-CdA in a dose of 4 mg/ kg/d is too high in this combination treatment and should be decreased to 2 mg/kg/d for 7 d in phase II of the study (35) . Similar studies were undertaken by Saven et al., who evaluated the safety pro®le of a combination treatment with 2-CdA and mitoxantrone in previously treated LG-NHL patients (23) . The authors found that the maximum tolerated dose (MTD) of mitoxantrone in this combination was 7.5 mg/m 2 on day 1, and MTD of 2-CdA was 0.1 mg/kg/d when administered in continuous iv infusion for 7 d. In our study, the dose of mitoxantrone and cyclophosphamide was similar to that administered by other authors in combination with 2-CdA in previously treated patients. We have applied 2-CdA in a dose of 0.12 mg/kg/d for 3 or 5 d. Our results prove that the shorter time of 2-CdA administration, for 3 d (CMC3) instead of for 5 d (CMC5), may be equally effective and better tolerated. The rate of response in both groups was similar but the adverse events were less frequent when 2-CdA administration was shortened. The reduction in neutropenia and infections was particularly important, although the difference was not signi®cant due to the small number of patients and low power of statistical analysis. Laurencet et al. administered 2-CdA in a dose of 0.1 mg/kg/d for 3 d subcutaneously in combination with cyclophosphamide 500/m 2 iv on day 1 in CLL and LG-NHL patients (21) . They concluded that such a combination was ef®cient and safe in patients with indolent lymphoid malignancies. In the recently published phase I/II study, van Den Neste et al. established that in pre-treated CLL and LG-NHL patients who were given 2-CdA in a dose of 5.6 mg/m 2 /d, also for 3 d, the MTD for cyclophosphamide was 300 mg/ m 2 /d if given iv for 3 d (20) . The response rate in this study was 58%, including 15% CR. The main toxicity was, similar to our study, myelosuppression and infections. The importance of 2-CdA dose reduction is also implied by Betticher et al., who decreased the dose in pre-treated patients from 0.7 mg/kg/d to 0.5 mg/kg/d iv for 5 d (38) . The reduced dose of 2-CdA was no less ef®cient in terms of response, while the incidence of myelosuppression and infections was signi®cantly decreased.
In conclusion, the combined chemotherapy with 2-CdA, mitoxantrone and cyclophosphamide shows signi®cant therapeutic activity in pre-treated CLL and LG-NHL patients, with acceptable toxicity. A shorter administration of 2-CdA (3 instead of 5 d) does not seem to affect the ef®cacy but may reduce myelosuppression and the frequency of infections. Whether the CMC combination therapy is superior to 2-CdA in monotherapy in CLL patients is the subject of a randomised clinical trial that has been undertaken by our group.
